Endo in a Bite

This episode reviews major updates in ASCVD risk stratification and lipid management from the AHA/ACC lipid guideline. Topics include cumulative apolipoprotein B exposure assessment, updated low density lipoprotein cholesterol estimation methods, expanded clinical use of apolipoprotein B and lipoprotein(a), integration of cardiovascular kidney metabolic syndrome into preventive cardiology, revised triglyceride referral thresholds, PREVENT ASCVD risk equations, high sensitivity C-reactive protein guided statin therapy considerations, and the evolving role of coronary artery calcium scoring in refining lipid lowering intensity and individualized cardiovascular risk reduction.

This episode reviews major updates in lipid management for ASCVD risk reduction. Topics include revised LDL-C estimation equations, expanded clinical application of apolipoprotein B for residual atherogenic risk assessment, universal lipoprotein(a) screening, and cardiovascular kidney metabolic syndrome as a risk enhancing condition. The episode also discusses triglyceride referral thresholds, reproductive and inflammatory ASCVD risk enhancers, high sensitivity C-reactive protein guided statin considerations, and the role of coronary artery calcium scoring in refining lipid lowering therapy and cardiovascular risk stratification.

This episode applies risk based lipoprotein targets across specific clinical scenarios for atherosclerotic cardiovascular disease risk reduction. It highlights how severe hypercholesterolemia, diabetes, subclinical atherosclerosis, hypertriglyceridemia, and clinical ASCVD are stratified using the same three tier framework of 100/130/90, 70/100/70, and 55/85/55. It emphasizes the role of coronary artery calcium in refining risk, the use of apoB to assess atherogenic particle burden, and the distinction between patients with and without established ASCVD. It also reinforces that diabetes without ASCVD does not meet criteria for the most intensive targets and that consistent numeric thresholds guide management across varying clinical presentations.

This episode reviews risk based lipoprotein targets for atherosclerotic cardiovascular disease risk reduction. It highlights LDL-C, non-HDL-C, and apolipoprotein B as key parameters, with goals stratified by overall ASCVD risk category. It emphasizes the three tier framework of 100/130/90 for low risk, 70/100/70 for intermediate risk, and 55/85/55 for high or very high risk patients. It also covers primary versus secondary prevention targets, the role of apoB in refining atherogenic burden, especially in hypertriglyceridemia, and the importance of assigning risk first before applying lipid goals in clinical practice.

This episode reviews the clinical application of lipoprotein(a) and apolipoprotein B in cardiovascular risk assessment based on AHA ACC guidance. It emphasizes the genetic determination and stability of lipoprotein(a), supporting its role as a one time measurement for risk stratification, along with the importance of cascade screening in identifying inherited risk. The discussion outlines how lipoprotein(a) levels correlate with graded increases in cardiovascular risk and contribute to atherosclerosis, thrombosis, and calcific aortic valve disease. It also highlights apolipoprotein B as a direct measure of atherogenic particle burden, providing additional risk refinement beyond traditional cholesterol metrics, particularly in patients with metabolic disease or discordant lipid profiles. Key takeaways include appropriate use of advanced lipid markers, integration with PREVENT risk estimation, recommended monitoring strategies during lipid lowering therapy, and evidence based thresholds for treatment intensification to reduce long term cardiovascular risk..

This episode reviews standard lipid measurements for cardiovascular risk assessment based on AHA/ACC guidelines. It highlights the use of non-fasting lipid testing for most patients, key indications for fasting testing, and modern LDL cholesterol calculation methods. It also covers the role of non-HDL cholesterol and the limited utility of advanced lipoprotein testing in clinical practice.

This episode reviews the importance of dyslipidemia screening across both pediatric and adult populations based on AHA ACC guidelines. It highlights the epidemiology and clinical impact of dyslipidemia, emphasizing the role of cumulative low density lipoprotein cholesterol exposure in determining lifetime cardiovascular risk. The discussion covers universal screening strategies, limitations of family history based screening, and practical approaches to identifying high risk individuals, including those with familial hypercholesterolemia. Key takeaways include recommended screening intervals, age based strategies, appropriate use of lipid testing, and the importance of early detection and intervention to reduce long term cardiovascular morbidity and mortality.

This episode reviews the clinical significance of hypoglycemia in diabetes care, including its classification into Level 1, Level 2, and Level 3 events. The discussion highlights early recognition, variability in symptom thresholds, and the importance of prompt treatment to prevent severe outcomes. Key takeaways include the use of 15 to 20 grams of fast acting carbohydrates for conscious patients, appropriate use of glucagon in severe cases, and strategies to reduce recurrence through patient education and individualized care.

This episode reviews the evolution of vitamin D management frameworks, highlighting the shift from intake based recommendations by the National Academy of Medicine to the 2011 Endocrine Society’s laboratory driven approach, and back to a modern intake focused strategy in the 2024 guideline. The discussion emphasizes when vitamin D testing is appropriate, the role of 25 hydroxyvitamin D in assessing stores, and why routine screening is no longer recommended in healthy individuals. Key clinical takeaways include evidence based supplementation for specific populations such as older adults, pregnancy, and high risk prediabetes, along with a preference for consistent daily dosing over intermittent high dose regimens.

This episode reviews clinical management of gastrointestinal symptoms associated with semaglutide therapy and strategies to maintain treatment when intolerance occurs. The discussion explains the role of delayed gastric emptying in nausea and highlights practical approaches including dietary modification, slower dose titration, and symptom directed therapy.
Additional topics include pregnancy planning with the recommended 8 week washout period before conception and emerging evidence for kidney protection from the SUSTAIN 6 and FLOW trials demonstrating reduction in nephropathy progression and cardiovascular events in patients with type 2 diabetes.